These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

42 related articles for article (PubMed ID: 1398464)

  • 21. Effect of subcutaneous injection of a long-acting analogue of somatostatin (SMS 201-995) on plasma thyroid-stimulating hormone in normal human subjects.
    Itoh S; Tanaka K; Kumagae M; Takeda F; Morio K; Kogure M; Hasegawa M; Horiuchi T; Watabe T; Miyabe S
    Life Sci; 1988; 42(26):2691-9. PubMed ID: 2898717
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Postprandial gallbladder motility during long term treatment with the long-acting somatostatin analog SMS 201-995 in acromegaly.
    van Liessum PA; Hopman WP; Pieters GF; Jansen JB; Smals AG; Rosenbusch G; Kloppenborg PW; Lamers CB
    J Clin Endocrinol Metab; 1989 Sep; 69(3):557-62. PubMed ID: 2760170
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Postprandial exocrine pancreatic function during long-term treatment with the somatostatin analogue SMS 201-995 in acromegalic patients.
    Van Liessum PA; Hopman WP; Pieters GF; Smals AG; Tangerman A; Jansen JB; Rosenbusch G; Lamers CB
    Eur J Clin Invest; 1990 Aug; 20(4):348-53. PubMed ID: 2121494
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic dopamine receptor stimulation using bromocriptine: failure to modify thyroid function.
    Köbberling J; Darragh A; Del Pozo E
    Clin Endocrinol (Oxf); 1979 Oct; 11(4):367-70. PubMed ID: 117954
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Effects of biliary lithogenesis in acromegalic patients with long-term octreotide (SMS 201-995) treatment].
    Buscail LE; Puel-Bousquet C; Harris AG; Tauber JP; Escourrou JR; Delvaux MM; Vaysse NM; Bayard F; Ribet A
    Gastroenterol Clin Biol; 1991; 15(11):800-4. PubMed ID: 1769469
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lack of antibody formation during long-term subcutaneous treatment with the somatostatin analogue octreotide in acromegaly.
    van Liessum PA; Swinkels LM; Pieters GF; Ross AA; Smals AG; Benraad TJ; Kloppenborg PW
    Acta Endocrinol (Copenh); 1990 Mar; 122(3):309-12. PubMed ID: 2183534
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of psoriasis with chronic subcutaneous administration of somatostatin analog 201-995 (sandostatin). II. Effect on pancreatic and thyroid hormone.
    Camisa C; Schacht GE; O'Dorisio TM; Maceyko RF
    Cleve Clin J Med; 1990; 57(1):77-81. PubMed ID: 2407389
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pancreatic exocrine and gallbladder function during long-term treatment with octreotide (SMS 201-995).
    Hopman WP; van Liessum PA; Pieters GF; Smals AG; Tangerman A; Jansen JB; Rosenbusch G; Lamers CB; Kloppenborg PW
    Digestion; 1990; 45 Suppl 1():72-6. PubMed ID: 2185969
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of 4 weeks of octreotide treatment on prolactin, thyroid stimulating hormone and thyroid hormones in acromegalic patients. A double blind placebo-controlled cross-over study.
    Andersen M; Hansen TB; Bollerslev J; Bjerre P; Schrøder HD; Hagen C
    J Endocrinol Invest; 1995 Dec; 18(11):840-6. PubMed ID: 8778155
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SMS 201-995 and thyroid function in acromegaly: acute, intermediate and long-term effects.
    Christensen SE; Weeke J; Kaal A; Harris AG; Orskov H
    Horm Metab Res; 1992 May; 24(5):237-9. PubMed ID: 1398464
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth hormone responses.
    Pieters GF; van Liessum PA; Smals AG; van Gennep JA; Benraad TJ; Kloppenborg PW
    Acta Endocrinol Suppl (Copenh); 1987; 286():9-18. PubMed ID: 2892339
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Behavior of the pituitary-thyroid axis in acromegalic subjects during prolonged intermittent and pulsatile treatment with octreotide].
    Cuttica CM; Fazzuoli L; Cariola G; Carraro A; Porcella E; Giusti M; Giordano G
    Recenti Prog Med; 1994 Jan; 85(1):7-12. PubMed ID: 8184183
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Paradoxic elevation in serum GH by hypothalamic releasing hormones predicts GH response to acute SMS 201-995 administration.
    Candrina R
    Recenti Prog Med; 1991 Jan; 82(1):13-6. PubMed ID: 1902962
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TSH producing pituitary tumor: biochemical diagnosis and long-term medical management with octreotide.
    Chayen SD; Gross D; Makhoul O; Glaser B
    Horm Metab Res; 1992 Jan; 24(1):34-8. PubMed ID: 1612557
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.